Reed Michael Lee 4

What Happened

• Reed Michael Lee, a director of Nutex Health, was granted 603 restricted stock units (RSUs) on July 14, 2025. The RSUs are reported at $0.00 (no cash paid) and represent a contingent right to receive one share of common stock per RSU upon vesting. This was an equity award/compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: July 14, 2025; Form 4 filed February 9, 2026 (filed well after the typical 2-business-day window).
• Instrument and amount: 603 RSUs granted, reported at $0.00 per unit (derivative award).
• Vesting: 100% of the RSUs vest on July 14, 2026. If the reporting person leaves service without cause during the vesting period, vesting occurs on a pro-rata basis for actual time in service. (Footnotes detail these terms.)
• Shares owned following transaction: not specified in the Form 4 filing.
• Filing timeliness: The Form 4 was filed several months after the grant date, reducing the immediacy of disclosure for investors.

Context

• RSU grants are typically routine compensation for directors and executives and do not by themselves indicate buying or selling intent. These RSUs are derivative awards that will convert into actual shares only upon vesting and settlement. For valuation or materiality, check the company's proxy statement or other disclosures for grant-date fair value details.